{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:59:12Z","timestamp":1794373152987,"version":"4.9.0"},"reference-count":96,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Respiratory Medicine"],"published-print":{"date-parts":[[2026,1,2]]},"DOI":"10.1080\/17476348.2025.2569844","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:25:15Z","timestamp":1759299915000},"page":"49-62","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Advances in type 2-high asthma therapy: what remains missing?"],"prefix":"10.1080","volume":"20","author":[{"given":"Ahmad Z.","family":"Al Meslamani","sequence":"first","affiliation":[{"name":"Al Ain University","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anan S.","family":"Jarab","sequence":"additional","affiliation":[{"name":"Jourdan University of Science and Technology","place":["Irbid, Jordan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Elrefae","sequence":"additional","affiliation":[{"name":"Northwick Park Hospital","place":["Harrow, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.05.028"},{"key":"e_1_3_5_4_1","unstructured":"Allergy Asthma Network. When asthma is more than just asthma: type 2 inflammation [Internet]. 2021 [cited 2025 Jul 3]. Available from: https:\/\/allergyasthmanetwork.org\/news\/when-asthma-more-than-asthma-type-inflammation\/"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S439089"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.051"},{"key":"e_1_3_5_7_1","unstructured":"GINA. Global strategy for asthma management and prevention [Internet]. 2024 [cited 2025 Jun 24]. Available from: https:\/\/ginasthma.org\/2024-report\/"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(25)00037-2"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2302583"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2284213"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2291078"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000969"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12018"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.03.017"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15755"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2023.15.3.290"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2023.1229238"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.228421310"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.11.2102005"},{"key":"e_1_3_5_20_1","unstructured":"AAFA. 2024 asthma capitals [internet]. 2024 [cited 2025 Aug 29]. Available from: https:\/\/aafa.org\/asthma-allergy-research\/our-research\/asthma-capital"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcrj.2006.09.002"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2012.33.3599"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.allmed.2025.100062"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1255"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70029"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.648506"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231205431"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.202.Supp.119.5"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15949"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646450"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.09.016"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-024-02233-w"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186892"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.11.007"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2277864"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0178-2021"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202502-0504ED"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.921967"},{"key":"e_1_3_5_40_1","unstructured":"Hoffmann-La Roche. A study of lebrikizumab in participants with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication [internet]. Clinicaltrials.gov ID NCT01867125. 2017 [cited 2025 Jul 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01867125#xd_co_f=MDI0NjUxMzAtZTA5NS00MTlhLTlmN2YtODVkMGNiNjM0YmQy~"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.08.604"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1138-3"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00197-6"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30412-4"},{"key":"e_1_3_5_45_1","unstructured":"Reuters. Novartis drops asthma drug fevipiprant after trial failures [Internet]. 2019 [cited 2025 Jul 21]. Available from: https:\/\/www.reuters.com\/article\/business\/healthcare-pharmaceuticals\/novartis-drops-asthma-drug-fevipiprant-after-trial-failures-idUSKBN1YK0DQ\/#:~:text=ZURICH%28Reuters%29 another set of key trials"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24641"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-14-93"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2023.207.1_MeetingAbstracts.A6816"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13864"},{"key":"e_1_3_5_50_1","first-page":"42","article-title":"Depemokimab in eosinophilic asthma - a new era in biological therapy?","volume":"31","author":"Pillay S","year":"2025","unstructured":"Pillay S. Depemokimab in eosinophilic asthma - a new era in biological therapy? Afr J Thorac Crit Care Med South Africa. 2025;31:42.","journal-title":"Afr J Thorac Crit Care Med South Africa"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406673"},{"key":"e_1_3_5_52_1","article-title":"Type IV hypersensitivity reaction","author":"Marwa K","year":"2025","unstructured":"Marwa K, Goldin J, Kondamudi NP. Type IV hypersensitivity reaction. Treasure Isl (FL). 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562228\/.","journal-title":"Treasure Isl (FL)"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S69932"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2215425"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091108"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.03.044"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54670-8"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.740803"},{"key":"e_1_3_5_59_1","unstructured":"ClinicalTrials.gov. Study to assess the efficacy and safety of atuliflapon in moderate-to-severe uncontrolled asthma (FLASH) [Internet]. 2025 [cited 2025 Jul 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05251259?rank=1"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2024.PA2995"},{"key":"e_1_3_5_61_1","unstructured":"Verona Pharma. Verona Pharma announces US FDA approval of OhtuvayreTM (ensifentrine) [Internet]. 2024 [cited 2025 Aug 29]. Available from: https:\/\/www.veronapharma.com\/news\/verona-pharma-announces-us-fda-approval-of-ohtuvayre-ensifentrine\/"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01157-2024"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-0944OC"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.07.168"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70011"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S78049"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0912-y"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.983852"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2249237"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221212"},{"key":"e_1_3_5_71_1","unstructured":"US FDA. Fda requires warnings about increased risk of serious heart-related events cancer blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions. [Internet]. [cited 2025 Jul 22]. Available from: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"key":"e_1_3_5_72_1","unstructured":"Sanofi. Media update: new results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma [Internet]. 2024 [cited 2025 Jul 22]. Available from: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-05-22-17-15-00-2886776"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.03.002"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.10.001"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.09.014"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.21037\/sci-2022-025"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v17.i2.103599"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1177\/09636897231180128"},{"key":"e_1_3_5_79_1","unstructured":"Dupixent. Pricing and Insurance [Internet]. Prescription medications have a not pay the list price 2025 **large real-world pooled analysis showing reductions in oral corticosteroid use after biologic initiation\u2014practice-changing evidence for OCS-sparing impact. 2025 [cited 2025 Jul 23]. Available from: https:\/\/www.dupixent.com\/support-savings\/cost-insurance#:~:text=All"},{"key":"e_1_3_5_80_1","unstructured":"Xolair. Xolair pricing and financial support [internet]. 2025 [cited 2025 Jul 23]. Available from: https:\/\/www.xolair.com\/cost.html#:~:text=What could I expect to pay."},{"key":"e_1_3_5_81_1","unstructured":"Rind DM Campbell J Herce-Hagiwara B et al. Tezepelumab for severe asthma [Internet]. 2023. Available from: https:\/\/icer.org\/wp-content\/uploads\/2021\/05\/Severe-Asthma_Revised-Report_061423.pdf."},{"key":"e_1_3_5_82_1","unstructured":"ICER. Institute for Clinical and Economic Review report finds biologic treatments for uncontrolled asthma would require more than a 50% price discount to reach common thresholds for cost-effectiveness. [Internet]. 2018 [cited 2025 Jul 23]. Available from: https:\/\/icer.org\/news-insights\/press-releases\/institute-for-clinical-and-economic-review-report-finds-biologic-treatments-for-uncontrolled-asthma-would-require-more-than-a-50-price-discount-to-reach-common-thresholds-for-cost-effectiveness\/#:~:text=Econom"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.12.010"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.23034"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2024.2448736"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2024.2324855"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02437-y"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.2147\/POR.S497033"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.12.027"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2025.102375"},{"key":"e_1_3_5_91_1","unstructured":"GINA. Global strategy for asthma management and prevention (2025 update) [Internet]. 2025 [cited 2025 Jul 23]. Available from: https:\/\/ginasthma.org\/wp-content\/uploads\/2025\/05\/GINA-Strategy-Report_2025-WEB-WMS.pdf?"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2024-7-2"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.04.032"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07608-5"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.04.039"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S507008"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16434"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.0746"}],"container-title":["Expert Review of Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17476348.2025.2569844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:06:46Z","timestamp":1767960406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17476348.2025.2569844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"alternative-id":["10.1080\/17476348.2025.2569844"],"URL":"https:\/\/doi.org\/10.1080\/17476348.2025.2569844","relation":{},"ISSN":["1747-6348","1747-6356"],"issn-type":[{"value":"1747-6348","type":"print"},{"value":"1747-6356","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}